1
|
Kuriki Y, Sogawa M, Komatsu T, Kawatani M, Fujioka H, Fujita K, Ueno T, Hanaoka K, Kojima R, Hino R, Ueo H, Ueo H, Kamiya M, Urano Y. Modular Design Platform for Activatable Fluorescence Probes Targeting Carboxypeptidases Based on ProTide Chemistry. J Am Chem Soc 2024; 146:521-531. [PMID: 38110248 DOI: 10.1021/jacs.3c10086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2023]
Abstract
Carboxypeptidases (CPs) are a family of hydrolases that cleave one or more amino acids from the C-terminal of peptides or proteins and play indispensable roles in various physiological and pathological processes. However, only a few highly activatable fluorescence probes for CPs have been reported, and there is a need for a flexibly tunable molecular design platform to afford a range of fluorescence probes for CPs for biological and medical research. Here, we focused on the unique activation mechanism of ProTide-based prodrugs and established a modular design platform for CP-targeting florescence probes based on ProTide chemistry. In this design, probe properties such as fluorescence emission wavelength, reactivity/stability, and target CP can be readily tuned and optimized by changing the four probe modules: the fluorophore, the substituent on the phosphorus atom, the linker amino acid at the P1 position, and the substrate amino acid at the P1' position. In particular, switching the linker amino acid at position P1 enabled us to precisely optimize the reactivity for target CPs. As a proof-of-concept, we constructed probes for carboxypeptidase M (CPM) and prostate-specific membrane antigen (also known as glutamate carboxypeptidase II). The developed probes were applicable for the imaging of CP activities in live cells and in clinical specimens from patients. This design strategy should be useful in studying CP-related biological and pathological phenomena.
Collapse
Affiliation(s)
- Yugo Kuriki
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Mari Sogawa
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Toru Komatsu
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Minoru Kawatani
- Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
- Department of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuda-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
| | - Hiroyoshi Fujioka
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
- Department of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuda-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
| | - Kyohhei Fujita
- Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Tasuku Ueno
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Kenjiro Hanaoka
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Ryosuke Kojima
- Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| | - Rumi Hino
- Department of Sports and Health Science, Daito Bunka University, 560 Iwadono, Higashimatsuyama, Saitama 355-8501, Japan
| | - Hiroki Ueo
- Ueo Breast Cancer Hospital, 1-3-5 Futamatacho, Oita, Oita 870-0887, Japan
| | - Hiroaki Ueo
- Ueo Breast Cancer Hospital, 1-3-5 Futamatacho, Oita, Oita 870-0887, Japan
| | - Mako Kamiya
- Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
- Department of Life Science and Technology, Tokyo Institute of Technology, 4259, Nagatsuda-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
- Living Systems Materialogy (LiSM) Research Group, International Research Frontiers Initiative (IRFI), Tokyo Institute of Technology, 4259, Nagatsuda-cho, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
| | - Yasuteru Urano
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
- Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
| |
Collapse
|
2
|
Masuda T, Ueo H, Okumura Y, Kai Y, Ando Y, Masuguchi K, Kitagawa M, Kitagawa A, Hayashi N, Tsuruda Y, Hisamatsu Y, Suehiro S, Ohmura H, Fujiyoshi K, Tanaka F, Mimori K. Dynamic Changes in Peripheral Systemic Immunity Markers During Chemotherapy in HER2-negative Advanced Breast Cancer. Cancer Genomics Proteomics 2023; 20:182-194. [PMID: 36870689 PMCID: PMC9989675 DOI: 10.21873/cgp.20373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 12/15/2022] [Accepted: 12/19/2022] [Indexed: 03/06/2023] Open
Abstract
BACKGROUND/AIM The immune system has a pivotal role in modulating the response to chemotherapy in breast cancer (BC). However, the immune status during chemotherapy remains unclear. We evaluated the sequential changes in peripheral systemic immunity markers in BC patients treated with various chemotherapeutic agents. MATERIALS AND METHODS We examined the correlation between the peripheral systemic immunity markers, neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC) and the local cytolytic activity (CYT) score obtained by quantitative reverse-transcription polymerase chain reaction of 84 preoperative BC patients. Next, we observed the sequential changes in the peripheral systemic immunity markers during treatment with four anticancer drugs: oral 5-fluorouracil derivative; S-1, epirubicin plus cyclophosphamide; paclitaxel plus the anti-vascular endothelial growth factor antibody bevacizumab, and eribulin in 172 HER2-negative advanced BC patients. Finally, we examined the correlation between the changes in the peripheral systemic immunity markers, time to treatment failure (TTF) and progression-free survival (PFS). RESULTS A negative correlation was found between ALC and NLR. ALC-low and NLR-high cases were positively associated with CYT score-low cases. The ratio of ALC-increase and NLR-decrease varies depending on the anticancer drugs used. The responder group (TTF ≥3 months) had a higher NLR-decrease ratio than the nonresponder group (TTF <3 months). Patients with a high NLR-decrease ratio showed higher PFS. CONCLUSION The change in ALC or NLR varies according to the anticancer drugs, suggesting differential immunomodulatory effects of the drugs. Furthermore, the change in NLR reflects the therapeutic efficacy of chemotherapy in advanced BC.
Collapse
Affiliation(s)
- Takaaki Masuda
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan
| | | | - Yuta Okumura
- Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan
| | | | - Yuki Ando
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan
| | - Ken Masuguchi
- Department of Pharmacy, Kyushu University Beppu Hospital, Oita, Japan
| | - Miwa Kitagawa
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.,Department of Breast Surgery, Medical Corporation Kyoujinkai Komatsu Hospital, Osaka, Japan
| | - Akihiro Kitagawa
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.,Department of Surgery, Sakai City Medical Center, Osaka, Japan
| | - Naoki Hayashi
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan
| | - Yusuke Tsuruda
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan
| | - Yuichi Hisamatsu
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan
| | - Shuji Suehiro
- Department of Breast Surgery, Tsurumi Hospital, Oita, Japan
| | - Hirofumi Ohmura
- Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan
| | | | - Fumiaki Tanaka
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan.,Tanaka Breast, Surgery, Internal Medicine Clinic, Oita, Japan
| | - Koshi Mimori
- Department of Surgery, Kyushu University Beppu Hospital, Oita, Japan;
| |
Collapse
|
3
|
Nomizu T, Ueo H, Kato M, Fukuma E. [Efficacy and Safety of Scalp Cooling Device RV21-01 for Suppression of Chemotherapy-Induced Alopecia in Breast Cancer Patients]. Gan To Kagaku Ryoho 2023; 50:321-325. [PMID: 36927900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
We evaluated the efficacy and safety of the RV21-01 scalp cooling device in controlling hair loss during chemotherapy in this study. Thirty-nine breast cancer patients who underwent anthracycline- and/or taxane-based chemotherapy were assigned to the scalp cooling group(27 patients)and the hair loss observation group(12 patients). The alopecia rate using the NCI alopecia toxicity criteria and the quantitative alopecia toxicity grade was 51.9%(14/27 patients)and 100%(12/12 patients)in the scalp cooling and hair loss observation groups, respectively. Regarding safety, all subjects in both the scalp cooling and hair loss observation groups experienced adverse events; only 1 subject in each group experienced a severe adverse event due to chemotherapy and majority of the subjects in both groups experienced minor adverse events. RV21-01 scalp cooling therapy was demonstrated to be effective in reducing hair loss in patients undergoing standard chemotherapy for breast cancer. In addition, the adverse events associated with the scalp cooling therapy were minor and mild, and hence, deemed acceptable.
Collapse
|
4
|
Ueo H, Ueo H, Minoura I, Gamachi A, Doi T, Yamaguchi M, Yamashita T, Tsuda H, Moriya T, Yamaguchi R, Kozuka Y, Sasaki T, Masuda T, Kai Y, Kubota Y, Urano Y, Mori M, Mimori K. Clinical usefulness of a novel fluorescence technique for the intraoperative diagnosis of surgical margins in patients with breast cancer. Br J Surg 2021; 108:e340-e342. [PMID: 34428279 DOI: 10.1093/bjs/znab265] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 06/02/2021] [Accepted: 06/22/2021] [Indexed: 11/12/2022]
Abstract
In both 5- and 15-min data, FI was significantly higher in malignant tissues than in benign tissues. The diagnostic accuracy was similar at 5 and 15 min. Therefore, the 5-min FI was enough applying in the further analyses.
Collapse
Affiliation(s)
- H Ueo
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.,Ueo Breast Cancer Hospital, Oita, Japan
| | - H Ueo
- Ueo Breast Cancer Hospital, Oita, Japan
| | - I Minoura
- Goryo Chemical, Inc., Sapporo, Japan
| | - A Gamachi
- Department of Pathology, Almeida Memorial Hospital, Oita, Japan
| | - T Doi
- Breast Cancer Centre, Shonan Memorial Hospital, Kamakura, Japan
| | - M Yamaguchi
- Department of Breast Surgery, JCHO Kurume General Hospital, Kurume, Japan
| | - T Yamashita
- Department of Breast and Endocrine Surgery, Kanagawa Cancer Centre, Yokohama, Japan
| | - H Tsuda
- Department of Basic Pathology, National Defence Medical College, Tokorozawa, Japan
| | - T Moriya
- Department of Pathology, Kawasaki Medical School, Kurashiki, Japan
| | - R Yamaguchi
- Department of Pathology and Laboratory Medicine, Kurume University Medical Centre, Kurume, Japan
| | - Y Kozuka
- Department of Pathology, Mie University Hospital, Tsu, Japan
| | - T Sasaki
- Department of Next-Generation Pathology Information and Networking, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
| | - T Masuda
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan
| | - Y Kai
- Ueo Breast Cancer Hospital, Oita, Japan
| | - Y Kubota
- Ueo Breast Cancer Hospital, Oita, Japan
| | - Y Urano
- Graduate School of Medicine and Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
| | - M Mori
- Department of Surgery and Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Japan
| |
Collapse
|
5
|
Fujita K, Kamiya M, Yoshioka T, Ogasawara A, Hino R, Kojima R, Ueo H, Urano Y. Rapid and Accurate Visualization of Breast Tumors with a Fluorescent Probe Targeting α-Mannosidase 2C1. ACS Cent Sci 2020; 6:2217-2227. [PMID: 33376783 PMCID: PMC7760471 DOI: 10.1021/acscentsci.0c01189] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2020] [Indexed: 05/21/2023]
Abstract
Accurate detection of breast tumors and discrimination of tumor from normal tissues during breast-conserving surgery are essential to reduce the risk of misdiagnosis or recurrence. However, existing probes show substantial background signals in normal breast tissues. In this study, we focus on glycosidase activities in breast tumors. We synthesized a series of 12 fluorescent probes and performed imaging-based evaluation on surgically resected human breast specimens. Among them, the α-mannosidase-reactive fluorescent probe HMRef-αMan detected breast cancer with 90% sensitivity and 100% specificity. We identified α-mannosidase 2C1 as the target enzyme and confirmed its overexpression in various breast tumors. We found that fibroadenoma, the most common benign breast lesion in young woman, tends to have higher α-mannosidase 2C1 activity than malignant cancer. Combined application of green-emitting HMRef-αMan and a red-emitting γ-glutamyltranspeptidase probe enabled efficient dual-color, dual-target optical discrimination of malignant and benign tumors.
Collapse
Affiliation(s)
- Kyohhei Fujita
- Graduate School of Medicine and Graduate School
of Pharmaceutical Sciences, The University
of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Mako Kamiya
- Graduate School of Medicine and Graduate School
of Pharmaceutical Sciences, The University
of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- PRESTO,
Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Takafusa Yoshioka
- Graduate School of Medicine and Graduate School
of Pharmaceutical Sciences, The University
of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Akira Ogasawara
- Graduate School of Medicine and Graduate School
of Pharmaceutical Sciences, The University
of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - Rumi Hino
- Daito
Bunka University, Department of Sports and
Health Science, 560 Iwadono, Higashimatsuyama, Saitama 355-8501, Japan
| | - Ryosuke Kojima
- Graduate School of Medicine and Graduate School
of Pharmaceutical Sciences, The University
of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- PRESTO,
Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan
| | - Hiroaki Ueo
- Ueo
Breast Cancer Hospital, 1-3-5 Futamatacho, Oita, Oita 870-0887, Japan
| | - Yasuteru Urano
- Graduate School of Medicine and Graduate School
of Pharmaceutical Sciences, The University
of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- CREST,
Japan
Agency for Medical Research and Development, 1-7-1 Otemachi, Chiyoda,
Tokyo 100-0004, Japan
- E-mail
| |
Collapse
|
6
|
Kijima Y, Koriyama C, Fujii T, Hirokaga K, Ishigure K, Kaneko T, Kayano S, Miyamoto S, Sagara Y, Sakurai T, Sakurai T, Sotome K, Ueo H, Wakita K, Watatani M. Erratum to immediate breast volume replacement using a free dermal fat graft after breast cancer surgery: multi-institutional joint research of short-term outcomes in 262 Japanese patients. Gland Surg 2018; 6:756-757. [PMID: 29302500 DOI: 10.21037/gs.2017.12.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
[This corrects the article on p. 179 in vol. 4, PMID: 26005649.].
Collapse
Affiliation(s)
- Yuko Kijima
- Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan
| | - Chihaya Koriyama
- Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan
| | - Teruhiko Fujii
- Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan
| | - Kouichi Hirokaga
- Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan
| | | | | | - Shuji Kayano
- Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan
| | | | - Yasuaki Sagara
- Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan
| | - Takashi Sakurai
- Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan
| | - Teruhisa Sakurai
- Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan
| | | | | | | | - Masahiro Watatani
- Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| |
Collapse
|
7
|
Takamori S, Toyokawa G, Ueo H, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Shoji F, Okamoto T, Maehara Y. Family-associated factors influence the postoperative prognosis in patients with non-small cell lung cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx384.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Ito S, Kai Y, Masuda T, Tanaka F, Matsumoto T, Kamohara Y, Hayakawa H, Ueo H, Iwaguro H, Hedrick MH, Mimori K, Mori M. Long-term outcome of adipose-derived regenerative cell-enriched autologous fat transplantation for reconstruction after breast-conserving surgery for Japanese women with breast cancer. Surg Today 2017; 47:1500-1511. [PMID: 28555267 DOI: 10.1007/s00595-017-1544-4] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Accepted: 05/02/2017] [Indexed: 12/17/2022]
Abstract
PURPOSE More effective methods are needed for breast reconstruction after breast-conserving surgery for breast cancer. The aim of this clinical study was to assess the perioperative and long-term outcomes of adipose-derived regenerative cell (ADRC)-enriched autologous fat grafting. METHODS Ten female patients who had undergone breast-conserving surgery and adjuvant radiotherapy for breast cancer were enrolled. An ADRC-enriched fat graft prepared from the patient's adipose tissue was implanted at the time of adipose tissue harvest. The perioperative and long-term outcomes of the grafts, which included safety, efficacy, and questionnaire-based patient satisfaction, were investigated. RESULTS The mean operation time was 188 ± 30 min, and the mean duration of postoperative hospitalization was 1.2 ± 0.4 days. No serious postoperative complications were associated with the procedure. Neither recurrence nor metastatic disease was observed during the follow-up period (7.8 ± 1.5 years) after transplantation. Of 9 available patients, "more than or equal to average" satisfaction with breast appearance and overall satisfaction were reported by 6 (66.7%) and 5 (55.6%) patients, respectively. CONCLUSIONS ADRC-enriched autologous fat transplantation is thus considered to be safe perioperatively, with no long-term recurrence, for patients with breast cancer treated by breast-conserving surgery, and it may be an option for breast reconstruction, even after adjuvant radiotherapy.
Collapse
Affiliation(s)
- Shuhei Ito
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan
| | - Yuichiro Kai
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan.,Ueo Breast Surgical Hospital, Oita, Japan
| | - Takaaki Masuda
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan
| | - Fumiaki Tanaka
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan
| | - Toshifumi Matsumoto
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan
| | - Yukio Kamohara
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan
| | | | | | | | | | - Koshi Mimori
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu, 874-0838, Japan.
| | - Masaki Mori
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Japan
| |
Collapse
|
9
|
Arima N, Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Koga T, Kurashita K, Todoroki H, Ueo H, Ohi Y, Toyoshima S, Mitsuyama S, Tamura K. Abstract P4-21-25: The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Anti-HER2 treatment using trastuzumab (Tmab) has contributed to improving the clinical outcome of HER2-positive breast cancerpatients. However, some patients do not respond to Tmab therapy and the combination of Lapatinib and capecitabine (LC) is an effective treatment option after progression on Tmab. Hormone receptor status is also an important factor for deciding if the patient should be treated with endocrine therapy as well. The aim of this study was to investigate the clinical significance of hormone receptor status in biomarker expression and to evaluate the efficacy of lapatinib therapy.
Materials and Methods: Eighty patients with HER2 positive breast cancer refractory to Tmab were enrolled in this prospective trial (KBC-SG 1107) between December 2011 and March 2014. The following treatment began after enrollment; lapatinib 1250-mg tablets were administered orally once daily and capecitabine (2000 mg/m2 per day) on days 1 to 14 every 21 days until disease progression or until severe adverse events. Total HER2 (H2T), p95HER2 (p95), and total HER3 (H3T) expression levels were quantified in formalin-fixed paraffin embedded samples using VeraTag assays. ER and progesterone receptor (PgR), PTEN and p95 expressions were evaluated using immunohistochemistry (IHC) and PIK3CA mutation using direct sequencing. Statistical analyses were performed using SPSS (ver. 21). A two-sided P<0.05 was considered a statistically significant difference.
Results: The ER- and PgR-positive rates were 55.0% and 33.8%, respectively. The response rate to LC was 30% (CR: 1 case; PR: 23 cases), the clinical benefit rate was 51.3% and the median progression-free survival (PFS) was 174.5 days. Both ER and PgR negativity significantly correlated with higher H2T (cutoff: 13.8), p95HER2 (cutoff: 2.8) and PTEN expression levels (cutoff: H score of 100). Lower H2T expression levels and PIK3CA mutation rates were often observed in the non-responders (both: p=0.087). The ER and PgR status did not correlate with response. A high p95 and PTEN expression significantly correlated with longer PFS in ER and/or PgR positive cases (p=0.02 and 0.03), respectively. The overall survival (OS) after LC significantly correlated with the number of recurrence organs (p=0.0002) but not with the p95 and PTEN expression levels.
Conclusion: LC therapy was effective in Tmab-refractory HER2 positive breast cancer. Moreover, the biomarker expression differed depending on the ER/PgR status and a high p95 and PTEN expression correlated with longer PFS in ER and/or PgR positive cases. Further study is necessary to validate these findings.
Citation Format: Arima N, Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Koga T, Kurashita K, Todoroki H, Ueo H, Ohi Y, Toyoshima S, Mitsuyama S, Tamura K. The importance of hormone receptor status on biomarker expression and the efficacy of lapatinib plus capecitabine therapy after progression on trastuzumab in HER2 positive recurrent and advanced breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-25.
Collapse
Affiliation(s)
- N Arima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - R Nishimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - U Toh
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - M Tanaka
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - M Saimura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - Y Okumura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - T Saito
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - T Tanaka
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - M Teraoka
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - K Shimada
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - T Koga
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - K Kurashita
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - H Todoroki
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - H Ueo
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - Y Ohi
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - S Toyoshima
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - S Mitsuyama
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| | - K Tamura
- Kumamoto Shinto General Hospital, Kumamoto, Japan; Kurume University School of Medicine, Kurume, Fukuoka, Japan; JCHO Kurume General Hospital, Kurume, Fukuoka, Japan; Kitakyushu Municipal Medical Center, Kitakyushu, Fukuoka, Japan; Kumamoto City Hospital, Kumamoto, Japan; Saitama Red Cross Hospital, Saitama, Japan; Fukuoka University, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; Shimada Breast Clinic, Kitakyushu, Fukuoka, Japan; Hirose Hospital, Fukuoka, Japan; Urasoe General Hospital, Urasoe, Okinawa, Japan; National Hospital Organization Kokura Medical Center, Kitakyushu, Fukuoka, Japan; Ueo Breast Cancer Hospital, Ooita, Japan; General Medical Research Center School of Medicine, Fukuoka University, Fukuoka, Japan
| |
Collapse
|
10
|
Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Ueo H, Arima N, Mitsuyama S, Tamura K. Correlation between HER2 related biomarkers (HER2, p95HER2, HER3, PTEN and PIK3CA) and treatment outcome of lapatinib plus capecitabine in HER2-positive metastatic breast cancer refractory to trastuzumab. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e12085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Reiki Nishimura
- Breast Center, Kumamoto Shinto General Hospital, Kumamoto City, Japan
| | - Uhi Toh
- Department of Surgery, Kurume Univ School of Medcn, Kurume-Shi, Japan
| | - Maki Tanaka
- JCHO Kurume General Hospital, Kurume City, Japan
| | | | | | - Tsuyoshi Saito
- Department of Breast Surgery, Saitama Red Cross Hospital, Saitama, Japan
| | - Toshihiro Tanaka
- Division of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University, Fukuoka, Japan
| | - Megumi Teraoka
- Department of Breast Surgical Oncology, Hakuaikai Sagara Hospital, Kagoshima City, Japan
| | | | - Kazuhisa Katayama
- Department of Surgerry, Isesaki Municipal Hospital, Isesaki City, Japan
| | | | | | - Satoshi Hasegawa
- Department of Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama City, Japan
| | - Hidekazu Todoroki
- Department of Surgery, National Hospital Organization @Kokura Medical Center, Kitakyushu City, Japan
| | - Hiroaki Ueo
- Ueo Breast Cancer Hospital, Oita City, Japan
| | - Nobuyuki Arima
- Department of Pathology, Kumamoto Shinto General Hospital, Kumamoto City, Japan
| | | | - Kazuo Tamura
- General Medical Research Center School of Medicine, Fukuoka University, Fukuoka City, Japan
| |
Collapse
|
11
|
Tanaka K, Tokunaga E, Inoue Y, Ueo H, Yamashita N, Sagara Y, Ohi Y, Taguchi K, Ohno S, Okano S, Kitao H, Oki E, Oda Y, Maehara Y. Abstract P5-13-05: The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background.
The estrogen receptor (ER)/ GATA3/ Forkhead box A1 (FOXA1) network is necessary for the ERα functional signature specific to luminal type breast cancers. High expression of FOXA1 indicates a good prognosis in ER-positive breast cancer. However, little is known about the association between the expression of FOXA1 and GATA3, and the efficacy of neoadjuvant endocrine therapy (NAE). This study investigated their predictive potential for NAE and the changes of their expression after NAE.
Methods.
The expression of ER, progesterone receptor (PgR), Ki67, FOXA1, and GATA3 were analyzed by immunohistochemistry in 66 patients with hormone receptor-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer who had been treated with NAE between March 2003 and December 2012 at Kyushu University Hospital, National Kyushu Cancer Center, and Sagara Hospital. The association between the expression of biological marker and the efficacy of NAE, and their expression changes after NAE were evaluated.
Results.
The median age of the patients was 60 years (range, 30–84 years). Pre- and post-menopausal patients were 24 (36.4%) and 42 (63.6%). Endocrine agents that were administered are as follows: aromatase inhibitors (AIs) for 42 patients (63.6%), luteinizing hormone-releasing hormone (LHRH) agonist plus AI for 10 patients (15.2%), LHRH agonist plus tamoxifen for 13 patients (19.7%). NAE yielded a partial response (PR) in 21 patients (31.8%) and stable disease (SD) in 45 patients (68.2%). Breast conserving surgery was performed in 56 patients (84.8%) and mastectomy was performed in 10 patients (15.2%). Preoperative Endocrine Prognostic Index (PEPI) score was 0 in 10 patients (15.2%) and 1 or greater (score 1 ≤) in 56 patients (84.8%).
Pre-treatment FOXA1 expression was positively correlated with GATA3 (P = 0.0003) and PgR (P = 0.0138). Post-treatment Ki67 expression was significantly lower in tumors, which achieved PR compared with those with SD (P = 0.0007). The expression of PgR, Ki67, and FOXA1 was significantly lower in post-treatment tumors compared with those in pre-treatment samples (p < 0.0001, p < 0.0001 and p < 0.0001, respectively). The expression of PgR, Ki67, and FOXA1 was significantly reduced in both tumors with PR and those with SD (PR: P = 0.0004, P < 0.0001, and P = 0.0417, respectively; SD: P < 0.0001, P = 0.0001, and P < 0.0001, respectively). The expression of PgR, Ki67, and FOXA1 was significantly decreased in post-treatment tumors in both patients with the PEPI score 0 and those with score 1 ≤ (score 0: P = 0.0078, P = 0.0059, and P = 0.0098, respectively; score 1 ≤: P < 0.0001, P < 0.0001, and P = 0.0002, respectively). In tumors with PgR > 20%, the expression of Ki67 and FOXA1 were significantly lower in post-treatment tumors (P < 0.0001 and P < 0.0001, respectively).
Conclusions.
FOXA1 expression correlated with PgR expression, and was reduced significantly after NAE. These results suggest that blocking the effect of estrogen might reduce FOXA1 expression.
Citation Format: Tanaka K, Tokunaga E, Inoue Y, Ueo H, Yamashita N, Sagara Y, Ohi Y, Taguchi K, Ohno S, Okano S, Kitao H, Oki E, Oda Y, Maehara Y. The relationship between the expression of FOXA1 and GATA3 and the efficacy of neoadjuvant endocrine therapy. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-13-05.
Collapse
Affiliation(s)
- K Tanaka
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - E Tokunaga
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Inoue
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - H Ueo
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - N Yamashita
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Sagara
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Ohi
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - K Taguchi
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - S Ohno
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - S Okano
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - H Kitao
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - E Oki
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Oda
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| | - Y Maehara
- Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Graduate School of Medical Sciences, Fukuoka, Japan; Sagara Hospital, Kagoshima, Japan; National Kyushu Cancer Centre, Fukuoka, Japan
| |
Collapse
|
12
|
Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, Shinden Y, Eguchi H, Yamamoto H, Doki Y, Mori M, Ochiya T, Mimori K. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer 2015; 113:275-81. [PMID: 26057451 PMCID: PMC4506387 DOI: 10.1038/bjc.2015.201] [Citation(s) in RCA: 372] [Impact Index Per Article: 41.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2015] [Revised: 04/06/2015] [Accepted: 05/06/2015] [Indexed: 12/11/2022] Open
Abstract
Background: Functional microRNAs (miRNAs) in exosomes have been recognised as potential stable biomarkers in cancers. The aim of this study is to identify specific miRNAs in exosome as serum biomarkers for the early detection of recurrence in human colorectal cancer (CRC). Methods: Serum samples were sequentially obtained from six patients with and without recurrent CRC. The miRNAs were purified from exosomes, and miRNA microarray analysis was performed. The miRNA expression profiles and copy number aberrations were explored using microarray and array CGH analyses in 124 CRC tissues. Then, we validated exosomal miRNAs in 2 serum sample sets (90 and 209 CRC patients) by quantitative real-time RT–PCR. Results: Exosomal miR-17-92a cluster expression level in serum was correlated with the recurrence of CRC. Exosomal miR-19a expression levels in serum were significantly increased in patients with CRC as compared with healthy individuals with gene amplification. The CRC patients with high exosomal miR-19a expression showed poorer prognoses than the low expression group (P<0.001). Conclusions: Abundant expression of exosomal miR-19a in serum was identified as a prognostic biomarker for recurrence in CRC patients.
Collapse
Affiliation(s)
- T Matsumura
- 1] Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
| | - K Sugimachi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Iinuma
- Department of Surgery, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo 173-0003, Japan
| | - Y Takahashi
- 1] Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
| | - J Kurashige
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - G Sawada
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - M Ueda
- 1] Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
| | - R Uchi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Ueo
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - Y Takano
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - Y Shinden
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Eguchi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Yamamoto
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
| | - Y Doki
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
| | - M Mori
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita City, Osaka 565-0871, Japan
| | - T Ochiya
- Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo 104-0045, Japan
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| |
Collapse
|
13
|
Kijima Y, Koriyama C, Fujii T, Hirokaga K, Ishigure K, Kaneko T, Kayano S, Miyamoto S, Sagara Y, Sakurai T, Sakurai T, Sotome K, Ueo H, Wakita K, Watatani M. Immediate breast volume replacement using a free dermal fat graft after breast cancer surgery: multi-institutional joint research of short-term outcomes in 262 Japanese patients. Gland Surg 2015; 4:179-94. [PMID: 26005649 DOI: 10.3978/j.issn.2227-684x.2015.01.06] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Accepted: 01/05/2015] [Indexed: 11/14/2022]
Abstract
BACKGROUND Immediate volume replacement using a free dermal fat graft (FDFG) has been proven safe with early postoperative benefits. The aims of the present study were to clarify adequate indications and risk factors associated with operative morbidity. PATIENTS AND METHODS A multi-institutional analysis of partial mastectomy with immediate volume replacement with FDFG was undertaken in 14 hospitals specializing in breast cancer treatment. Clinical and oncological variables were analyzed to identify factors associated with postoperative complications. RESULTS A total of 262 cases were analyzed. Considering the observation period and overlap of patients, 13 (5.4%) out of 242 patients had complications within 1 month of surgery while 7 (4.6%) out of 151 patients developed complications 1-12 months after surgery. Two hundred and eleven out of 242 patients were statistically examined using a multivariate analysis, which revealed that the weight of resected breast tissue, size of implanted FDFG (cranio-caudal length), and weight of implanted FDFG were associated with a higher likelihood of postoperative complications. CONCLUSIONS Immediate breast volume replacement using a FDFG after breast cancer surgery should be done for selected patients with breast cancer to avoid postoperative complications. The prospective and larger investigations are warranted for the establishment of appropriate guidelines.
Collapse
Affiliation(s)
- Yuko Kijima
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Chihaya Koriyama
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Teruhiko Fujii
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Kouichi Hirokaga
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Kiyoshi Ishigure
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Tomoyo Kaneko
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Shuji Kayano
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Sachio Miyamoto
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Yasuaki Sagara
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Takashi Sakurai
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Teruhisa Sakurai
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Keiichi Sotome
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Hiroaki Ueo
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Kazuyuki Wakita
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| | - Masahiro Watatani
- 1 Department of Digestive Surgery, Breast and Thyroid Surgery, 2 Department of Epidemiology and Preventive Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan ; 3 Breast Care Center, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan ; 4 Department of Breast Oncology, Hyogo Cancer Center, Hyogo, Japan ; 5 Department of Surgery, Konan Kosei Hospital, Aichi, Japan ; 6 Kaneko Clinic, Kagoshima, Japan ; 7 Plastic and Reconstructive Surgery Department, National Cancer Center Hospital, Tokyo, Japan ; 8 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan ; 9 Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan ; 10 Division of Surgery, Saitama Social Insurance Hospital, Saitama, Japan ; 11 Department of Surgery, Wakayama Medical University, Kihoku Hospital, Wakayama, Japan ; 12 Department of Surgery, Fussa Hospital, Tokyo, Japan ; 13 Ueo Breast Cancer Hospital, Oita, Japan ; 14 Chayamachi Breast Clinic, Osaka, Japan ; 15 Department of Breast Surgery, Kinki University Faculty of Medicine, Nara Hospital, Osaka, Japan
| |
Collapse
|
14
|
Watanabe T, Shimozuma K, Imi K, Doihara H, Akabane H, Ueo H, Ohno S, Kashiwaba M, Fukuuchi A, Watanabe K, Tsuneizumi M, Isaka H, Uemura Y, Ohashi Y, Mukai H. Abstract P3-10-01: Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR- MBC01). Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p3-10-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment goals of metastatic breast cancer (MBC) are to prolong survival and improve health-related quality of life (HRQOL). Current standard first-line chemotherapy for MBC are the taxanes or anthracyclines; however treatment-related adverse events greatly reduce HRQOL. S-1 is an oral 5-fluorouracil derivative, and phase II trials showed good clinical efficacy and tolerability. We conducted a phase III randomized controlled trial to establish non-inferiority of S-1 in overall survival (OS) and superiority in HRQOL to taxanes, when given as first-line chemotherapy for MBC.
Methods: Patients with HER2-negative non-life-threatening MBC, naïve to chemotherapy for metastatic disease, were randomly assigned to the taxane or S-1 groups. In the taxane group, patients received docetaxel 60-75mg/m2 q3w, paclitaxel 80-100mg/m2 q1w, or paclitaxel 175 mg/m2 q3w according to institutional policy. In the S-1 group, patients received S-1 40–60 mg twice daily based on body surface area using a 28 days on;14 days off regimen. Treatment was repeated until tumor progression or for at least 6 cycles (taxane) or 4 cycles (S-1). After failure of the first-line protocol therapy, another cytotoxic agent was administered, based on the investigator’s discretion. HRQOL was assessed with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, the Patient Neurotoxicity Questionnaire (PNQ) and the EQ-5D at baseline and 3, 6, 12 months after the start of the treatment. The primary endpoint was OS. Secondary endpoints were time to treatment failure (TTF), adverse events, and HRQOL.
Results: A total of 618 women were enrolled. After a median follow-up of 34.6 months, median OS was 37.2 months in the taxane group (n=309) and 35.0 months in the S-1 group (n=309) (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.86–1.27, non-inferiority test p=0.015). Median TTF was 8.9 months in the taxane group and 8.0 months in the S-1 group (HR 1.10, 95% CI 0.93–1.30, p=0.022). The incidence of the following grade 3-4 adverse events, allergic reaction, edema and sensory neuropathy, were statistically significantly more frequent in the taxane group (p=0.038, 0.0013 and 0.0077, respectively). Hematologic and non hematologic toxicities except above did not differ significantly between the two groups. The results of the EORTC QLQ-C30 under study treatment indicated that the S-1 was better than the taxanes in global health status/QOL (p=0.044), physical functioning (p=0.002), role functioning (p=0.002), emotional functioning (p=0.004), cognitive functioning (p=0.026), social functioning (p<0.0001), pain (p=0.042) and financial difficulties (p=0.003). EQ-5D utility scores were significantly higher in the S-1 group (p=0.033) during the first year. PNQ sensory and motor scores were significantly better in the S-1 group (p<0.0001 and p=0.0002, respectively).
Conclusions: This study clearly demonstrated that S-1 was superior to taxanes in terms of HRQOL and toxicity, without compromising the prolonged OS. S-1 should be considered as a new standard for first-line chemotherapy for MBC. We are conducting another similar trial (UMIN000005449) that compares first-line anthracycline with S-1 in terms of OS and HRQOL.
Citation Format: Takanori Watanabe, Kojiro Shimozuma, Kentaro Imi, Hiroyoshi Doihara, Hiromitsu Akabane, Hiroaki Ueo, Shinji Ohno, Masahiro Kashiwaba, Atsushi Fukuuchi, Kenichi Watanabe, Michiko Tsuneizumi, Hirotsugu Isaka, Yukari Uemura, Yasuo Ohashi, Hirofumi Mukai. Randomized phase III trial of taxanes versus S-1 as first-line chemotherapy for metastatic breast cancer (SELECT BC: CSPOR- MBC01) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-10-01.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Shinji Ohno
- 7National Hospital Organization Kyushu Cancer Center
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ueo H, Sugimachi K, Gorges TM, Bartkowiak K, Yokobori T, Müller V, Shinden Y, Ueda M, Ueo H, Mori M, Kuwano H, Maehara Y, Ohno S, Pantel K, Mimori K. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br J Cancer 2015; 112:1519-26. [PMID: 25880010 PMCID: PMC4453677 DOI: 10.1038/bjc.2015.132] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2014] [Revised: 03/08/2015] [Accepted: 03/16/2015] [Indexed: 11/09/2022] Open
Abstract
BACKGROUND Identification of promising biomarkers that predict the prognosis of patients with breast cancer is needed. In this study, we hypothesised that the expression of the epithelial-mesenchymal transition-related biomarker plastin3 (PLS3) in peripheral blood could be a prognostic factor in breast cancer. METHODS We examined PLS3 expression in breast cancer cell lines with epithelial and mesenchymal traits and in circulating tumour cells (CTCs) obtained from the peripheral blood of breast cancer patients. We investigated PLS3 expression in the peripheral blood of 594 patients with breast cancer to evaluate the clinical significance of PLS3 expression. RESULTS Robust PLS3 expression was observed in different breast cancer cell lines (Hs578t, MCF-7, MDA-MB-468, and MDA-MB-231) as well as in a bone marrow derived cancer cell line (BC-M1). In both the training (n=298) and validation (n=296) sets, PLS3 expression was observed in CTCs of patients with breast cancer. PLS3-positive patients showed significantly poorer overall and disease-free survival than PLS3-negative patients (P=0.0001 and 0.003, respectively). Subset analysis revealed that this prognostic biomarker was relevant in patients with stage I-III cancer, particularly in patients with luminal-type and triple-negative-type tumours. CONCLUSIONS These data demonstrated that PLS3 was expressed in CTCs undergoing the epithelial-mesenchymal transition in patients with breast cancer. Furthermore, PLS3 may be an excellent biomarker for identifying groups at risk of recurrence or with a poor prognosis.
Collapse
Affiliation(s)
- H Ueo
- 1] Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan [2] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - K Sugimachi
- 1] Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan [2] Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - T M Gorges
- Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
| | - K Bartkowiak
- Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
| | - T Yokobori
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, 3-39-22 Showamachi, Maebashi 371-0034, Japan
| | - V Müller
- Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
| | - Y Shinden
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - M Ueda
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Ueo
- Department of Surgery, Ueo Breast Surgical Hospital, 188-2 Haya, Oita 870-0854, Japan
| | - M Mori
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan
| | - H Kuwano
- Department of General Surgical Science, Graduate School of Medicine, Gunma University, 3-39-22 Showamachi, Maebashi 371-0034, Japan
| | - Y Maehara
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - S Ohno
- Department of Breast Oncology, Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1347, Japan
| | - K Pantel
- Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D-20246 Hamburg, Germany
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| |
Collapse
|
16
|
Yamamoto Y, Anan K, Tanaka M, Maeda S, Ueo H, Sagara Y, Ohno S, Iwase H, Mitsuyama S, Tamura K. P213 Neoadjuvant nab-paclitaxel followed by FEC for operable breast cancer: KBC-SG 1103 trial. Breast 2015. [DOI: 10.1016/s0960-9776(15)70247-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Sugimachi K, Matsumura T, Hirata H, Uchi R, Ueda M, Ueo H, Shinden Y, Iguchi T, Eguchi H, Shirabe K, Ochiya T, Maehara Y, Mimori K. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br J Cancer 2015; 112:532-8. [PMID: 25584485 PMCID: PMC4453648 DOI: 10.1038/bjc.2014.621] [Citation(s) in RCA: 230] [Impact Index Per Article: 25.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2014] [Revised: 11/19/2014] [Accepted: 11/26/2014] [Indexed: 12/17/2022] Open
Abstract
Background Predictive biomarkers for the recurrence of hepatocellular carcinoma (HCC) have great benefit in the selection of treatment options, including liver transplantation (LT), for HCC. The purpose of this study was to identify specific microRNAs (miRs) in exosomes from the serum of patients with recurrent HCC and to validate these molecules as novel biomarkers for HCC recurrence. Methods We employed microarray-based expression profiling of miRs derived from exosomes in the serum of HCC patients to identify a biomarker that distinguishes between patients with and without HCC recurrence after LT. This was followed by the validation in a separate cohort of 59 HCC patients who underwent living related LT. The functions and potential gene targets of the recurrence-specific miRs were analysed using a database, clinical samples and HCC cell lines. Results We found that miR-718 showed significantly different expression in the serum exosomes of HCC cases with recurrence after LT compared with those without recurrence. Decreased expression of miR-718 was associated with HCC tumour aggressiveness in the validated cohort series. We identified HOXB8 as a potential target gene of miR-718, and its upregulation was associated with poor prognosis. Conclusion Circulating miRs in serum exosomes have potential as novel biomarkers for predicting HCC recurrence.
Collapse
Affiliation(s)
- K Sugimachi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - T Matsumura
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Hirata
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - R Uchi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - M Ueda
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Ueo
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - Y Shinden
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - T Iguchi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - H Eguchi
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| | - K Shirabe
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - T Ochiya
- Group for Research of Molecular Functions and Targets, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
| | - Y Maehara
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, 4546 Tsurumihara, Beppu 874-0838, Japan
| |
Collapse
|
18
|
Yumimoto K, Akiyoshi S, Ueo H, Sagara Y, Onoyama I, Ueo H, Ohno S, Mori M, Mimori K, Nakayama KI. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. J Clin Invest 2015; 125:621-35. [PMID: 25555218 DOI: 10.1172/jci78782] [Citation(s) in RCA: 91] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 11/20/2014] [Indexed: 02/06/2023] Open
Abstract
The gene encoding F-box protein FBXW7 is frequently mutated in many human cancers. Although most previous studies have focused on the tumor-suppressive capacity of FBXW7 in tumor cells themselves, we determined that FBXW7 in the host microenvironment also suppresses cancer metastasis. Deletion of Fbxw7 in murine BM-derived stromal cells induced accumulation of NOTCH and consequent transcriptional activation of Ccl2. FBXW7-deficient mice exhibited increased serum levels of the chemokine CCL2, which resulted in the recruitment of both monocytic myeloid-derived suppressor cells and macrophages, thereby promoting metastatic tumor growth. Administration of a CCL2 receptor antagonist blocked the enhancement of metastasis in FBXW7-deficient mice. Furthermore, in human breast cancer patients, FBXW7 expression in peripheral blood was associated with serum CCL2 concentration and disease prognosis. Together, these results suggest that FBXW7 antagonizes cancer development in not only a cell-autonomous manner, but also a non-cell-autonomous manner, and that modulation of the FBXW7/NOTCH/CCL2 axis may provide a potential approach to suppression of cancer metastasis.
Collapse
|
19
|
Shinden Y, Akiyoshi S, Ueo H, Nambara S, Saito T, Komatsu H, Ueda M, Hirata H, Sakimura S, Uchi R, Takano Y, Iguchi T, Eguchi H, Sugimachi K, Kijima Y, Ueo H, Natsugoe S, Mimori K. Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res 2015; 35:123-127. [PMID: 25550542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
BACKGROUND/AIM MiR-15a targets Cyclin E1 (CCNE1), which regulates the cell cycle and promotes cell proliferation and progression. Herein, we investigated the clinicopathological significance of miR-15a as a prognostic marker in breast cancer (BC) cases. MATERIALS AND METHODS We collected primary tumor samples of 230 BC cases, including 68 triple-negative cases. The expression levels of miR-15a in primary tumors were measured by qRT-PCR assay. RESULTS Low expression of miR-15a in primary tumors was significantly correlated with shorter disease-free survival (p=0.0012) and overall survival (p=0.005) compared to the high miR-15a expression in triple-negative BC cases. Multivariate analysis indicated that low miR-15a expression was an independent prognostic factor for overall survival [RR=2.56(1.03-7.18), p=0.04]. CONCLUSION MiR-15a expression levels could be a promising biological and prognostic marker for overall survival especially in triple-negative BC cases.
Collapse
Affiliation(s)
- Yoshiaki Shinden
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan
| | - Sayuri Akiyoshi
- National Hospital Organization Kyushu Cancer Center, Minamiku, Fukuoka, Fukuoka, Japan
| | - Hiroki Ueo
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Syo Nambara
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Tomoko Saito
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Hisateru Komatsu
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Masami Ueda
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Hidenari Hirata
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Shotaro Sakimura
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Ryutaro Uchi
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Yuki Takano
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Tomohiro Iguchi
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Hidetoshi Eguchi
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Keishi Sugimachi
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| | - Yuko Kijima
- Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan
| | - Hiroaki Ueo
- Ueo Breast Surgery Hospital, Haya, Oita, Japan
| | - Shoji Natsugoe
- Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan
| | - Koshi Mimori
- Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan
| |
Collapse
|
20
|
Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, Yamamoto H, Doki Y, Mori M, Mimori K. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2013; 110:164-71. [PMID: 24196785 PMCID: PMC3887297 DOI: 10.1038/bjc.2013.698] [Citation(s) in RCA: 242] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2013] [Revised: 10/08/2013] [Accepted: 10/11/2013] [Indexed: 12/16/2022] Open
Abstract
Background: We previously conducted gene expression microarray analyses to identify novel indicators for colorectal cancer (CRC) metastasis and prognosis from which we identified PVT-1 as a candidate gene. PVT-1, which encodes a long noncoding RNA, mapped to chromosome 8q24 whose copy-number amplification is one of the most frequent events in a wide variety of malignant diseases. However, PVT-1 molecular mechanism of action remains unclear. Methods: We conducted cell proliferation and invasion assays using colorectal cancer cell lines transfected with PVT-1siRNA or negative control siRNA. Gene expression microarray analyses on these cell lines were also carried out to investigate the molecular function of PVT-1. Further, we investigated the impact of PVT-1 expression on the prognosis of 164 colorectal cancer patients by qRT–PCR. Results: CRC cells transfected with PVT-1 siRNA exhibited significant loss of their proliferation and invasion capabilities. In these cells, the TGF-β signalling pathway and apoptotic signals were significantly activated. In addition, univariate and multivariate analysis revealed that PVT-1 expression level was an independent risk factor for overall survival of colorectal cancer patients. Conclusion: PVT-1, which maps to 8q24, generates antiapoptotic activity in CRC, and abnormal expression of PVT-1 was a prognostic indicator for CRC patients.
Collapse
Affiliation(s)
- Y Takahashi
- 1] Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - G Sawada
- 1] Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - J Kurashige
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - R Uchi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - T Matsumura
- 1] Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan [2] Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - H Ueo
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - Y Takano
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - H Eguchi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - T Sudo
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - K Sugimachi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| | - H Yamamoto
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - Y Doki
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - M Mori
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita 565-0871, Japan
| | - K Mimori
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara 4546, Beppu 874-0838, Japan
| |
Collapse
|
21
|
Ono M, Koga T, Ueo H, Nakano S. Effects of Dietary Genistein on Hormone-Dependent Rat Mammary Carcinogenesis Induced by Ethyl Methanesulphonate. Nutr Cancer 2012; 64:1204-10. [DOI: 10.1080/01635581.2012.718035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
22
|
Kosaka Y, Kataoka A, Yamaguchi H, Ueo H, Akiyoshi S, Sengoku N, Kuranami M, Ohno S, Watanabe M, Mimori K, Mori M. Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer. Breast Cancer Res 2012; 14:R140. [PMID: 23113927 PMCID: PMC4053119 DOI: 10.1186/bcr3345] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Accepted: 09/03/2012] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION Identification of useful markers associated with poor prognosis in breast cancer patients is critically needed. We previously showed that expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful to predict distant metastasis in gastric cancer patients. However, expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood of breast cancer patients has not yet been studied. METHODS Real-time reverse transcriptase-PCR was used to analyze vascular endothelial growth factor receptor-1 mRNA expression status with respect to various clinical parameters in 515 patients with breast cancer and 25 controls. RESULTS Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood was higher in breast cancer patients than in controls. Increased vascular endothelial growth factor receptor-1 mRNA expression was associated with large tumor size, lymph node metastasis and clinical stage. Patients with high vascular endothelial growth factor receptor-1 mRNA expression also experienced a poorer survival rate than those with low expression levels, including those patients with triple-negative type and luminal-HER2(-) type disease. CONCLUSIONS Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful for prediction of poor prognosis in breast cancer, especially in patients with triple-negative type and luminal-HER2(-) type disease.
Collapse
|
23
|
Shibuta K, Mori M, Mimori K, Inoue H, Nakashima H, Baba K, Haraguchi M, Karimine N, Ueo H, Akiyoshi T. Expression of prothymosin-alpha and c-myc mRNA in human gastric cancer. Int J Oncol 2012; 9:247-51. [PMID: 21541507 DOI: 10.3892/ijo.9.2.247] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Prothymosin-alpha (PT-alpha) is a nuclear protein involved in cell proliferation. c-myc is implicated in the carcinogenesis of many human cancers. PT-alpha gene transcription is reported to be regulated by the c-myc gene in vitro. However, little has been reported on the PT-alpha and c-myc mRNA expressions in gastric cancer. We semi-quantitatively determined the PT-alpha and c-myc mRNA expressions in 60 pairs of gastric cancer tissue (T) and corresponding normal tissue (N) using the reverse transcriptase-polymerase chain reaction method. The average of T/N ratio was 1.20 for PT-alpha and 1.30 for c-myc. Cases demonstrating a T/N ratio of more than 1.0 were seen in 33 (55%) and 30 (50%) cases for PT-alpha and c-myc, respectively. No significant correlation was observed between either of these two mRNA expressions and any of the examined clinicopathologic factors for gastric cancer. However, a significant correlation was seen between the expressions of both genes (p<0.0001). The findings support the hypothesis that, regarding human gastric cancer, the transcription of PT-alpha is considered to be under the control of c-myc gene, however, the value of these gene expressions do not reflect biological behavior.
Collapse
Affiliation(s)
- K Shibuta
- KYUSHU UNIV,MED INST BIOREGULAT,DEPT SURG,BEPPU,OITA 874,JAPAN. OITA PREFECTURAL HOSP,DEPT SURG,OITA,JAPAN
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Nakashima H, Mori M, Mimori K, Inoue H, Baba K, Shibuta K, Kusumoto H, Haraguchi M, Ueo H, Akiyoshi T. Microsatellite instability in Japanese colorectal carcinoma. Oncol Rep 2012; 4:387-9. [PMID: 21590065 DOI: 10.3892/or.4.2.387] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Recent studies have shown that microsatellite instability (MSI) play an important role in the development of various types of cancer. To clarify the clinicopathologic significance of MSI in colorectal carcinoma (CRC), the presence of MSI was examined in 54 Japanese cases of CRC using the polymerase chain reaction-based method. The incidence of MSI in CRC cases was 13 out of 54 cases (24%). CRC with MSI also showed a significant tendency not to have lymph node metastasis (P<0.05), although neither the survival nor the prognosis of the cases examined in this study were available due to the short period of follow-up. The present study showed that the incidence of MSI in Japanese CRC was 24% and suggests that CRC with MSI may behave in a less malignant manner.
Collapse
Affiliation(s)
- H Nakashima
- KYUSHU UNIV,MED INST BIOREGULAT,DEPT SURG,BEPPU,OITA 874,JAPAN. KYUSHU UNIV,FAC MED,DEPT SURG 2,FUKUOKA 812,JAPAN. OITA PREFECTURAL HOSP,DEPT SURG,OITA,JAPAN
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, Sasako M, Maehara Y, Mimori K, Mori M. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer 2012; 107:1345-53. [PMID: 22955854 PMCID: PMC3494440 DOI: 10.1038/bjc.2012.326] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND We previously reported that bone marrow (BM) was a homing site for gastric cancer (GC) cells leading to haematogenous metastases. There has been little study that microRNAs regulated pathways in malignant cells or host cells in BM, and thereby regulated the progression of GC. METHODS Both microRNA microarray and gene expression microarray analyses of total RNA from BM were conducted, comparing five early and five advanced GC patients. We focused on miR-144-ZFX axis as a candidate BM regulator of GC progression and validated the origin of the microRNA expression in diverse cell fractions (EpCAM(+)CD45(-), EpCAM(-)CD45(+), and CD14(+)) by magnetic-activated cell sorting (MACS). RESULTS Quantitative reverse-transcriptase (RT)-PCR analysis validated diminished miR-144 expression in stage IV GC patients with respect to stage I GC patients (t-test, P=0.02), with an inverse correlation to ZFX (ANOVA, P<0.01). Luciferase reporter assays in five GC cell lines indicated their direct binding and validated by western blotting. Pre-miR144 treatment and the resultant repression of ZFX in GC cell lines moderately upregulated their susceptibility to 5-fluorouracil chemotherapy. In MACS-purified BM fractions, the level of miR-144 expression was significantly diminished in disseminated tumour cell fraction (P=0.0005). Diminished miR-144 expression in 93 cases of primary GC indicated poor prognosis. CONCLUSION We speculate that disseminated cancer cells could survive in BM when low expression of miR-144 permits upregulation of ZFX. The regulation of the miR-144-ZFX axis in cancer cells has a key role in the indicator of the progression of GC cases.
Collapse
Affiliation(s)
- S Akiyoshi
- Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Ono M, Koga T, Ueo H, Nakano S. Effect of Dietary Genistein on Hormone‐dependent Rat Mammary Carcinoma Induced by Ethyl Methanesulphonate (EMS). FASEB J 2012. [DOI: 10.1096/fasebj.26.1_supplement.1023.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Misaki Ono
- Graduate School of Health and Nutritional SciencesNakamura Gakuen UniversityFukuokaJapan
| | - Takaomi Koga
- Graduate School of MedicineKyushu UniversityFukuokaJapan
| | | | - Shuji Nakano
- Graduate School of Health and Nutritional SciencesNakamura Gakuen UniversityFukuokaJapan
| |
Collapse
|
27
|
Kasahara Y, Tsuji I, Ichimura M, Ueo H, Ohnuki K, Okazaki M, Koibuchi Y, Furukawa J, Murata Y, Morita T. Annual Report 2011 on Breast Cancer Screening in Japan. ACTA ACUST UNITED AC 2012. [DOI: 10.3804/jjabcs.21.48] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
28
|
Kayashima H, Ikegami T, Ueo H, Tsubokawa N, Matsuura H, Okamoto D, Nakashima A, Okadome K. Inflammatory pseudotumor of the liver in association with spilled gallstones 3 years after laparoscopic cholecystectomy: report of a case. Asian J Endosc Surg 2011; 4:181-4. [PMID: 22776305 DOI: 10.1111/j.1758-5910.2011.00094.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
We report on a case of a female patient diagnosed with inflammatory pseudotumor of the liver in association with spilled gallstones 3 years after laparoscopic cholecystectomy for calculous acute cholecystitis. She was asymptomatic, but CT revealed an intrahepatic mass and two other extrahepatic masses between the liver and the diaphragm. Furthermore, diffusion-weighted MRI and PET suggested all three lesions could be malignant tumors. As the preoperative diagnosis was intrahepatic cholangiocellular carcinoma with peritoneal disseminations, we performed a posterior segmentectomy of the liver combined with partial resection of the diaphragm. Histological examination showed the intrahepatic tumor was an inflammatory granuloma with abscess formations. There were bilirubin stones between the liver and the diaphragm. Therefore, the tumor was diagnosed as inflammatory pseudotumor of the liver in association with spilled gallstones. In conclusion, the liver tumor emerged after laparoscopic cholecystectomy and may involve inflammatory pseudotumor of the liver in association with spilled gallstones.
Collapse
Affiliation(s)
- H Kayashima
- Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Adachi K, Ueno T, Fujioka T, Fujitomi Y, Ueo H. Psychosocial Factors Affecting the Therapeutic Decision-making and Postoperative Mood States in Japanese Breast Cancer Patients who underwent Various Types of Surgery: Body Image and Sexuality. Jpn J Clin Oncol 2007; 37:412-8. [PMID: 17513308 DOI: 10.1093/jjco/hym041] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE We conducted an empirical study to clarify how psychosocial factors (e.g. body image and sexuality) influence therapeutic decision-making and to identify the factors that affect post-operative mood states in Japanese women who underwent various types of surgery. METHODS One hundred and two patients who had undergone surgical treatment for breast cancer participated in this study. Twenty-five patients had undergone mastectomy, 67 breast conserving treatment and 11 skin-sparing mastectomy and immediate breast reconstruction. The participants were evaluated based on a battery of questionnaires including value estimates of decision-making factors, a shortened version of the Profile of Mood States and self-efficacy. RESULTS The patients regarded the possibility of cure and recurrence of cancer as well as the physician's support as important, regardless of the treatments they had chosen. The patients that had immediate breast reconstruction placed significantly more importance on their body image and sexuality (i.e. physical appearance, attractiveness to partner and self-evaluation of femininity and sexuality) than the mastectomy patients. After surgery, the former group tended to have a more negative mood on the shortened version of the Profile of Mood States than the latter group. Degree of self-efficacy had a marked influence on the patients' mood after surgery. CONCLUSIONS This study suggests the importance of discussing body image and sexuality that has tended to be disregarded in therapeutic decision-making situations in breast cancer patients in Japan. Self-efficacy is a crucial variable for improving mood after treatment.
Collapse
|
30
|
Nakashima H, Karimine N, Asoh T, Ueo H, Kohnoe S, Mori M. Risk factors of abdominal surgery in patients with collagen diseases. Am Surg 2006; 72:843-8. [PMID: 16986398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Patients with collagen diseases have been reported to demonstrate a greater risk when undergoing surgical operations. To determine the risk factors in abdominal surgery for patients with collagen diseases, 32 patients with collagen diseases who underwent abdominal surgery were analyzed for their clinical features and surgical results by comparing 26 cases from the favorable prognosis group (Group A) and 6 cases resulting in hospital death (Group B). The analysis revealed that emergent operations tended to result in worse outcomes (P = 0.011) than elective operations and that cases undergoing operations for collagen disease-related problems, including intestinal perforation and acute pancreatitis, also showed a worse postoperative course than those who underwent operations for problems unrelated to collagen diseases, such as carcinomas and cholelithiasis (P = 0.0006). The dose of steroids administered at the time of operation was also significantly higher in Group B than in Group A (P = 0.03). These results suggested that the patients with collagen diseases should be followed periodically not only for the primary disease but also for any potential surgical diseases to identify such diseases at an early stage and to avoid an emergent operation, and that patients treated with high doses of steroids also need intensive care after abdominal surgery.
Collapse
Affiliation(s)
- Hideaki Nakashima
- Department of Innovative Medical Technology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
Patients with collagen diseases have been reported to demonstrate a greater risk when undergoing surgical operations. To determine the risk factors in abdominal surgery for patients with collagen diseases, 32 patients with collagen diseases who underwent abdominal surgery were analyzed for their clinical features and surgical results by comparing 26 cases from the favorable prognosis group (Group A) and 6 cases resulting in hospital death (Group B). The analysis revealed that emergent operations tended to result in worse outcomes ( P = 0.011) than elective operations and that cases undergoing operations for collagen disease-related problems, including intestinal perforation and acute pancreatitis, also showed a worse postoperative course than those who underwent operations for problems unrelated to collagen diseases, such as carcinomas and cholelithiasis ( P = 0.0006). The dose of steroids administered at the time of operation was also significantly higher in Group B than in Group A ( P = 0.03). These results suggested that the patients with collagen diseases should be followed periodically not only for the primary disease but also for any potential surgical diseases to identify such diseases at an early stage and to avoid an emergent operation, and that patients treated with high doses of steroids also need intensive care after abdominal surgery.
Collapse
Affiliation(s)
- Hideaki Nakashima
- Department of Innovative Medical Technology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | | | | | - Hiroaki Ueo
- Department of Surgery, Wada Hospital, Usa, Japan
| | - Shunji Kohnoe
- Department of Surgery, Fukuoka Dental College, Fukuoka, Japan
| | - Masaki Mori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| |
Collapse
|
32
|
Takeuchi H, Ueo H, Tsuji K, Tokunaga E, Baba H, Maehara Y. Prediction of survival from first recurrence of breast carcinoma in Japanese women. Breast 2006; 15:226-31. [PMID: 16005234 DOI: 10.1016/j.breast.2005.03.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2004] [Revised: 02/09/2005] [Accepted: 03/03/2005] [Indexed: 11/27/2022] Open
Abstract
The clinical courses of patients with recurrent breast carcinoma vary greatly. We retrospectively examined data on 1863 Japanese patients treated for a breast carcinoma from 1981 to 2000. Among them, 345 (18.5%) who had clearly died of recurrence were reviewed. Patients died most frequently (63.2%) up to 30 months after the first recurrence. Based on multivariate analysis, the four factors that were most predictive of survival after the first recurrence were disease-free interval, site of recurrence, progesterone receptor (PgR) status, and vascular involvement. These findings showed that the intrinsic tumor biology of the initial primary tumor plays a critical role in determining survival after the first recurrence in patients with a breast carcinoma. The combined analysis of disease-free interval, site of recurrence, PgR status, and vascular involvement may assist in estimating the median survival after first recurrence, and may assist with the designing of new therapeutic strategies for patients with recurrence for whom there is an unfavorable prognosis.
Collapse
Affiliation(s)
- Hideya Takeuchi
- Department of Surgery, Oita Prefectural Hospital, Bunyo 476, Oita 870-8511, Japan.
| | | | | | | | | | | |
Collapse
|
33
|
Inoue H, Shibuta K, Matsuyama A, Yoshinaga K, Sadanaga N, Ueo H, Barnard G, Mori M. Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncol Rep 2005. [DOI: 10.3892/or.14.3.707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
34
|
Inoue H, Shibuta K, Matsuyama A, Yoshinaga K, Sadanaga N, Ueo H, Barnard GF, Mori M. Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncol Rep 2005; 14:707-12. [PMID: 16077979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023] Open
Abstract
Polymorphic catechol-O-methyltransferase (COMT) catalyzes the O-methylation of catechol estrogens. It has been reported that COMT polymorphism is a representative genetic trait related to the susceptibility of an individual to breast cancer. However, there is no consensus concerning the association between breast cancer in Japanese patients and COMT polymorphism. To analyze the polymorphism distribution in Japanese patients with breast cancer, a molecular genotyping method using a polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) was used. Based on an analysis of 201 Japanese patients with breast cancer and 352 healthy control subjects, a significant difference was observed in either the distribution of genotypes (p=0.03) or allele frequencies between the two groups (p=0.01). The relative risk of breast cancer for genotypes (COMT(Met/Met) and COMT(Val/Met)) including the variant allele (COMT(Met)) was 1.47 compared to the wild allele (COMT(Val)) and homozygote (COMT(Val/Val)). Furthermore, the distribution of genotypes in post-menopausal patients with breast cancer showed a significant difference with that of healthy subjects of the same menopausal status (p=0.01). No significant difference was found between the distribution of genotypes and clinicopathological features of the cancer. These results suggest that COMT polymorphism may thus be implicated as a genetic trait affecting the susceptibility of an individual to breast cancer in a Japanese population and be an important genetic risk factor in the development of breast cancer in post-menopausal women.
Collapse
Affiliation(s)
- Hiroshi Inoue
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumibaru, Beppu 874-0838, Japan
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
BACKGROUND The clinical course of patients with recurrent breast carcinoma varies greatly. Better characterization of an individual's clinical course for recurrent patients may aid in their clinical management. However, less attention has been paid to evaluating factors associated with the timing of recurrence in those patients. We investigated the clinicopathological indicators that determined the timing of recurrence by univariate and multivariate analysis. METHODS We retrospectively examined data on 1428 curatively treated Japanese patients who had been surgically treated for breast cancer between 1983 and 2002. From these, 244(17.1%)who had clearly died of recurrence were entered into this study. RESULTS By univariate analysis, tumor size, estrogen receptor(ER), and progesterone receptor(PgR)were significantly correlated with time to recurrence. Multivariate analysis indicated that the time between operation and recurrence was independently influenced by ER and PR. CONCLUSIONS Our research shows that ER and PgR are independent factors influencing the timing of recurrence of breast carcinoma after curative resection. The combined analysis of these independent factors facilitates prediction of the time to recurrence for each patient.
Collapse
Affiliation(s)
- Hideya Takeuchi
- Department of Surgery, Oita Prefectural Hospital, Bunyo 476, Oita 870-8511, Japan.
| | | | | |
Collapse
|
36
|
Takeuchi H, Tsuji K, Ueo H, Kano T, Maehara Y. Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women. Breast Cancer Res Treat 2005; 88:49-54. [PMID: 15538045 DOI: 10.1007/s10549-004-9495-z] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Because of the rarity of apocrine carcinoma and lack of standardized criteria for the diagnosis, the definitive conclusions of clinicopathologic features and the prognosis has not been determined. We retrospectively examined data on 2091 curatively treated Japanese patients with primary breast carcinoma. Among them, 33 (1.6%) who had been diagnosed of apocrine carcinoma were reviewed. Compared with non-apocrine carcinoma, apocrine carcinoma was characterized by less positive rates of ER and PR, and by frequent rates of unilateral multicentric breast carcinoma with significant difference. The clinicopathological factors influencing 12-year survival rate were lymph node metastasis, lymphatic involvement and vascular involvement. There was no difference in survival rates at 10 years after operation between apocrine carcinoma and non-apocrine carcinoma. Our result shows unique hormone response and unilateral multicentricity are only typical clinicopathological features of apocrine carcinoma.
Collapse
Affiliation(s)
- Hideya Takeuchi
- Department of Surgery, Oita Prefectural Hospital, Bunyo 476, Oita, Japan.
| | | | | | | | | |
Collapse
|
37
|
Takeuchi H, Ueo H, Haraoka M, Maehara Y. Surgical results of total pelvic exenteration for locally advanced colorectal adenocarcinoma. Hepatogastroenterology 2005; 52:90-3. [PMID: 15783002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
BACKGROUND/AIMS Although total pelvic exenteration (TPE) may lead to local tumor control and improved quality of life in patients with locally advanced colorectal cancer, an adequate understanding of prognostic factors, indications and potential complications associated with these procedures is needed. METHODOLOGY Records for 15 patients, who underwent TPE for colorectal adenocarcinoma at Oita Prefectural Hospital between January 1983 and November 2001, were reviewed, retrospectively. RESULTS Ten (66.7%) had positive lymphatic involvement, seven (46.7%) had positive vascular involvement, and three (20%) had positive lymph node metastases. Bladder involvement histologically was evident in eight patients (53.3%). With regard to diagnostic assessment of bladder involvement using CT, the sensitivity and specificity were 83.3% and 60%, respectively. Six of 15 patients (40%) developed complications. Overall local recurrence was observed in 6 (40%) of the 15. The cumulative overall 5-year survival rate of the 15 patients in this study was 54.7%. In the univariate analysis, vascular involvement significantly influenced survival. CONCLUSIONS TPE appears to be relatively safe and effective for treatment of locally advanced colorectal adenocarcinoma. Vascular involvement was recognized as the only reliable prognostic clinicopathological characteristic.
Collapse
Affiliation(s)
- Hideya Takeuchi
- Department of Surgery, Oita Prefectural Hospital, Oita, Japan.
| | | | | | | |
Collapse
|
38
|
Mimori K, Ueo H, Kuroki T, Shiraishi T, Creer S, Taylor S, Ishii H, Mori M. Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes. Oncol Rep 2004. [DOI: 10.3892/or.12.1.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
39
|
Mimori K, Ueo H, Kuroki T, Shiraishi T, Creer S, Taylor S, Ishii H, Mori M. Prediction of 5'-deoxy-5-fluorouridine sensitivity in colorectal cancer cases by thymidine phosphorylase activity and preliminary identification of susceptibility related genes. Oncol Rep 2004; 12:19-23. [PMID: 15201953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Abstract
We confirmed that the enzyme activity of thymidine phosphorylase (TP) can substitute for 5'-deoxy-5-fluorouridine (5'-dFUR) sensitivity in clinical colorectal cancer (CRC) tissues. Moreover, the idenfication of susceptible genes other than TP will be desired for prediction or treatment of 5'-dFUR. We initially established conditions for the MTT assay system in vivo to compare the growth inhibition rate and TP activity in 18 cases of CRC. TP activity levels were concordant with 5'-dFUR sensitivity in the CRCs (p<0.05). In 18 CRC cases, 4 cases of high sensitivity and 3 cases of low sensitivity to 5'-dFUR were compared to analyze expression profiles of 9437 genes on cDNA microarray chips. As a result, a cluster of genes related to the sensitivity were identified and another cluster of genes related to the insensitivity of 5'-DFUR were also listed. We determined that TP expression can precisely predict 5'-dFUR sensitivity in CRCs and found susceptibility related genes.
Collapse
Affiliation(s)
- Koshi Mimori
- Department of Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan
| | | | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
BACKGROUND Male breast cancer accounts for less than 1% of all cancers in men. Compared to breast cancer in women, the natural history and prognosis of breast cancer in men is controversial. METHODS A retrospective review was performed for 15 cases of male breast carcinoma, who were surgically treated in the Department of Surgery, Oita Prefectual Hospital, Oita, Japan, between 1980 and 2001. RESULTS Two men were classified as presenting with stage 0 disease by the TNM classification, two as stage I, four as stage II, and six as stage III. Two received chemotherapy, four received hormone therapy, and seven received combined therapy. ER was positive in 7 of 10 patients, and PgR in 8 of 10. Only one patient died of tumor recurrence, and this was 15.9 years after surgery. A trend was observed toward negative nodal involvement, earlier TNM stage at diagnosis, and an increase in the use of modified radical mastectomy. CONCLUSIONS A favorable prognosis was recognized in male breast carcinoma, regardless of late stage, and hormonal therapy should be used for patients suffering from this disease.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Asian People/genetics
- Breast Neoplasms, Male/epidemiology
- Breast Neoplasms, Male/etiology
- Breast Neoplasms, Male/genetics
- Breast Neoplasms, Male/pathology
- Breast Neoplasms, Male/surgery
- Carcinoma, Ductal, Breast/epidemiology
- Carcinoma, Ductal, Breast/etiology
- Carcinoma, Intraductal, Noninfiltrating/epidemiology
- Carcinoma, Intraductal, Noninfiltrating/etiology
- Humans
- Japan/epidemiology
- Male
- Middle Aged
- Neoplasm Recurrence, Local/epidemiology
- Neoplasm Recurrence, Local/etiology
- Neoplasm Recurrence, Local/genetics
- Neoplasm Recurrence, Local/pathology
- Neoplasm Recurrence, Local/surgery
- Neoplasm Staging
- Prognosis
- Retrospective Studies
Collapse
Affiliation(s)
- Hideya Takeuchi
- Department of Surgery, Oita Prefectural Hospital, Bunyo 476, Oita 870-8511, Japan
| | | | | | | |
Collapse
|
41
|
Inoue H, Matsuyama A, Mimori K, Ueo H, Mori M. Prognostic score of gastric cancer determined by cDNA microarray. Clin Cancer Res 2002; 8:3475-9. [PMID: 12429637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
PURPOSE To estimate gastric cancer patients' prognosis more comprehensively,we tried to develop a prognostic scoring system using a cDNA microarray. EXPERIMENTAL DESIGN RNA was extracted from tumor/normal paired samples of 43 patients with gastric cancer, and cDNA microarray hybridization was performed. RESULTS We selected 78 genes that were differentially expressed between aggressive and nonaggressive groups with respect to five conventional pathological factors. Next, we determined a coefficient for each gene. Thereafter a prognostic score was calculated by summing-up the value for each gene. It ranged from -47 to 201 with a median of 114. There were two peaks in its distribution. Ten of 11 patients who were alive with no evidence of recurrence >5 years after the operation showed a score of <100 points, whereas all 19 patients who died of disease showed >100 points. In 13 patients who were alive but the follow-up time was <5 years, 2 of the 3 patients with >100 points revealed recurrent disease during the follow-up. CONCLUSIONS These findings demonstrate that such a system with cDNA microarray can contribute to the comprehensive analysis of malignant behavior of the tumor and may provide accurate information on prognosis.
Collapse
Affiliation(s)
- Hiroshi Inoue
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan
| | | | | | | | | |
Collapse
|
42
|
Abstract
The gene SMARCB1 has been considered a candidate for a tumor-suppressor gene. Nucleotide alterations in SMARCB1 have been reported, primarily in association with malignant rhabdoid tumor cases. We carried out a search for mutations in SMARCB1 in 60 human gastro-intestinal tract carcinoma cases, 122 breast cancer cases, and 36 human cancer cell lines. A single-nucleotide polymorphism (SNP) at codon 152 with an amino acid change (Asn to Asp) was found in 2 of 122 (1.6%) breast cancer cases, and another SNP at codon 299 without an amino acid change was found in tumor and normal tissues from 7 (5.7%) cases. Codons 152 and 299 of SMARCB1 are localized near or within the binding site for the cMYC protein. The amount of immunoprecipitated cMYC protein was reduced in two different cell lines expressing the codon 152 polymorphic SMARCB1 clone compared with those expressing wild-type SMARCB1, regardless of the identical expression of SMARCB1 protein in both cell lines. Therefore, the SNP at codon 152 is considered to be one of the coding SNPs that alters the SMARCB1-cMYC complex, which regulates various tumor-suppressor related genes against cancer. In addition, we identified three types of splicing isoforms, a 27-bp deleted gene, a 51-bp inserted gene, and a consensus gene, in both carcinoma tissues and in normal tissues; however, no clinical significance was observed for those isoforms. We found a nucleotide change at codon 152 of SMARCB1 that may alter the amount of immunoprecipitated cMYC protein, but we finally determined that SMARCB1 is highly conserved in human solid carcinomas.
Collapse
Affiliation(s)
- Koshi Mimori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | | | | | | | | | | | | |
Collapse
|
43
|
Mimori K, Matsuyama A, Yoshinaga K, Yamashita K, Masuda T, Inoue H, Ueo H, Mori M. Localization of thymidine phosphorylase expression in colorectal carcinoma tissues by in situ RT-PCR assay. Oncology 2002; 62:327-32. [PMID: 12138240 DOI: 10.1159/000065064] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Abundant expression of thymidine phosphorylase (TP) mRNA and protein was observed in human carcinoma tissues relative to the corresponding normal tissues. However, the distribution of cells that express TP has not yet been determined. In this study, we examined enzyme activity of TP in 24 primary colorectal carcinoma tissues and the corresponding normal tissue. Using in situ reverse-transcription polymerase chain reaction (RT-PCR), a new methodology to determine the localization of genes of interest objectively and clearly, cell distribution was compared. The expression of TP mRNA is observed in normal infiltrating cells adjacent to colon carcinoma cells by in situ RT-PCR. Similar to the protein activity, the average TP mRNA expression (amplified products/x400 field) in cases of Dukes C and D is 76.8, while that of Dukes A and B is 42.5, being significantly different (p = 0.001). Moreover, the number of amplified products in colon carcinoma tissues showed a significant correlation with the enzyme activity evaluated by high-performance liquid chromatography (p < 0.01, R = 0.76). In conclusion, the expression of TP mRNA is localized in stromal tissues as determined by in situ RT-PCR and can reflect the level of TP enzyme activity.
Collapse
Affiliation(s)
- Koshi Mimori
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Kimijima I, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]. Gan To Kagaku Ryoho 2002; 29:741-9. [PMID: 12040678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
In the first part of this late phase II study, we determined the recommended clinical dose of CGS20267 to be 1.0 mg once daily for the treatment of postmenopausal women with advanced or recurrent breast cancer. To further evaluate the efficacy and safety of CGS20267 at the derived or recommended clinical dose, 30 more patients were enrolled in the second part of the study, and were added to the patients treated at 1.0 mg in the first part. As a result of putting the first and second parts together, the objective response rate at 1.0 mg was found to be 38.3%, which was almost equal to that of the early phase II study (40.7%). Drug-related adverse events occurred in 35.4% of the patients at 1.0 mg, and all of the events were of grade 2 or lower. These results demonstrated that CGS20267 1.0 mg once daily is effective and well tolerated in the treatment of postmenopausal women with advanced or recurrent breast cancer.
Collapse
|
45
|
Abe R, Tominaga T, Nomizu T, Nomura Y, Takashima S, Koyama H, Sano M, Tohge T, Ueo H, Ikeda S, Ohashi Y. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]. Gan To Kagaku Ryoho 2002; 29:729-40. [PMID: 12040677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
To determine the recommended clinical dose of CGS20267 (Letrozole), we conducted a randomized comparative study as a late phase II study (first part) in postmenopausal women with advanced or recurrent breast cancer. Forty-one patients were randomly assigned to receive 0.5 mg or 1.0 mg once daily. There were no statistically significant differences in background between the two groups. Although there was no significant difference in the objective response rates between the two groups, the rate was higher at 1.0 mg (44.4%) than at 0.5 mg (38.1%). We also combined these data with the results of an early phase II study. The objective response rates (CR + PR) were 31.4% at 0.5 mg and 42.2% at 1.0 mg, and response rates consisting of CR, PR, and NC for longer than 6 months were significantly higher at a dose of 1.0 mg (68.9%) than 0.5 mg (41.2%). Side effects included drug-related adverse events in 36.8% at 0.5 mg and in 31.6% at 1.0 mg. All of the events were grade 2 or lower, indicating a favorable tolerability of CGS20267. These results demonstrated that CGS20267 1.0 mg once daily is more effective than 0.5 mg, and has comparable safety, in the treatment of postmenopausal women with advanced or recurrent breast cancer. We conclude the recommended clinical dose of CGS20267 should be 1.0 mg once daily.
Collapse
Affiliation(s)
- Rikiya Abe
- Dept. of Surgery II, Fukushima Medical College
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
OBJECTIVE N-Acetylation polymorphism is a representative genetic trait related to an individual's susceptibility to several cancers. However, there remains a controversy and no consensus concerning whether there is a true association between esophageal cancer and N-acetylation polymorphism. METHODS To analyze the distribution of N-acetyltransferase 2 polymorphism in Japanese patients with esophageal squamous cell cancer, a molecular genotyping method using a polymerase chain reaction-based restriction fragment length polymorphism was used. RESULTS Based on an analysis of 71 Japanese patients with esophageal squamous cell cancer and 329 healthy control subjects, the distribution of the slow acetylator phenotype was significantly higher in esophageal cancer patients than in the controls (19.7% and 9.4%, respectively, p = 0.040). The odds ratio of esophageal cancer for the slow phenotype was 2.55 (95% CI = 1.15-5.65, p = 0.023) compared with the rapid type. Furthermore, a significant difference between the distribution of acetylator phenotype and the incidence of lymph node metastasis and lymphatic involvement was found based on the clinicopathological features of these cancers. Esophageal cancer patients with a higher smoking exposure history tended to have the rapid acetylator phenotype. CONCLUSION These results suggest that N-acetylation polymorphism may be implicated as a genetic trait affecting an individual's susceptibility and biological behavior of esophageal squamous cell cancer.
Collapse
Affiliation(s)
- J Shibuta
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Kataoka A, Sadanaga N, Mimori K, Ueo H, Barnard GF, Sugimachi K, Auclair D, Chen LB, Mori M. Overexpression of HRad17 mRNA in human breast cancer: correlation with lymph node metastasis. Clin Cancer Res 2001; 7:2815-20. [PMID: 11555598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
PURPOSE A novel human gene, designated HRad17, was identified as the human homologue of the Rad17 of Schizosaccharomyces pombe and Rad24 of Saccharomyces cerevisiae. In yeast, these genes play a critical role in maintaining genomic stability. The aim of this study was to evaluate the expression of HRad17 in human breast cancer. EXPERIMENTAL DESIGN We investigated HRad17 mRNA expression in 64 cases of human breast cancer by means of reverse-transcription-PCR, in situ hybridization, and immunohistochemistry. RESULTS The HRad17 mRNA was overexpressed in 35 cases (54.7%). Twenty-four (68.6%) of 35 cases with HRad17 overexpression in cancer tissues were node-positive, whereas only 8 (27.6%) of 29 cases without HRad17 overexpressions were node-positive. The expression of HRad17 mRNA correlated with both lymph node metastasis (P = 0.001) and high Ki67 labeling index (P = 0.006). Although not significantly different, expression of HRad17 mRNA tended to correlate with tumor size (P = 0.06) and expression of mutant p53 protein (P = 0.10). Furthermore, expression of HRad17 mRNA was an independent predictor of axillary lymph node metastasis as well as of lymphatic permeation by multivariate analysis (P < 0.0001). CONCLUSIONS Our study demonstrates that HRad17 might be related to the development of lymph node metastasis in human breast cancers. Although its function still remains unclear, the expression of HRad17 mRNA could open up a new window for the diagnostic staging and treatment of human breast cancers.
Collapse
Affiliation(s)
- A Kataoka
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Etoh T, Ueo H, Inoue H, Sato K, Utsunomiya T, Barnard GF, Kitano S, Mori M. Clinical significance of K-Ras mutations in intraoperative tumor drainage blood from patients with colorectal carcinoma. Ann Surg Oncol 2001; 8:407-12. [PMID: 11407514 DOI: 10.1007/s10434-001-0407-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
BACKGROUND Recurrent and metastatic carcinoma of the colorectum remains a major problem. This may be ascribed to the presence of micrometastasis at diagnosis. The purpose of this study was to analyze prospectively the clinical value of detecting K-ras mutations in the perioperative circulating blood from patients with colorectal carcinoma. METHODS Twenty-four patients whose tumor carried mutations in codon 12 of the K-ras gene were studied for the presence of cancer cells in perioperative blood samples, in particular, tumor drainage samples. A detection assay using CD45 immunomagnetic separation plus nested mutant allele specific amplification (MASA) was performed. RESULTS K-ras mutations in CD45 negative cells in tumor drainage blood were detected in 7 (29.2%) of 24 patients. There was no significant relationship between the presence of a K-ras mutation and clinicopathological features. Four (57.1%) of the seven patients with a positive K-ras mutation in drainage blood had early recurrent disease. Of the 17 patients with no K-ras mutation, none developed metastatic disease. The recurrence rate of the K-ras mutation positive group was higher than that of the K-ras mutation negative group (P < .01). There was a significant difference, regarding prognosis, between K-ras mutation positive and negative groups (P < .01). CONCLUSIONS This preliminary study demonstrates that the detection of circulating cancer cells in the tumor drainage blood by our new assay system may provide a predictor of recurrence and metastasis of colorectal cancer.
Collapse
Affiliation(s)
- T Etoh
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Abstract
Recently, mammalian heparanase was cloned, and its probable function in tumor progression was reported. However, its expression in human clinical cancers has not been fully studied. Thus we determined the heparanase mRNA expression in 30 esophageal cancer cell lines and 144 clinical samples including 38 esophageal squamous cell carcinomas, 71 gastric adenocarcinomas, and 35 colorectal adenocarcinomas. The fresh surgical specimens of cancer tissue (T) and its paired normal tissue (N) were used. The heparanase mRNA was evaluated by reverse transcriptase-polymerase chain reaction, and the T/N expression ratio was determined in clinical cases. All 30 esophageal cancer cell lines expressed heparanase mRNA. The T/N ratio was determined as high (> or =1.3), equal (0.8 approximately 1.2) or low (< or = 0.7) in each clinical case. In cases of esophageal cancer, 7 showed high, 10 equal and 21 low expression. In cases of colorectal cancer, 3 showed high, 16 equal and 16 low expression. On the other hand, 42 showed high, 22 equal and 7 low expression in cases of gastric cancer. The frequency of high expression cases was greater in gastric cancer than in esophageal or colorectal cancers (p < 0.05). There were no differences in clinicopathologic factors including prognosis between high and low expression cases of each cancer. Our mRNA study of heparanase indicated that its expression status was different among gastrointestinal cancers. The clinical and pathological impact was low compared to other proteinases, although further studies are recommended for final conclusion.
Collapse
Affiliation(s)
- H Inoue
- Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu 874-0838, Japan
| | | | | | | | | | | | | |
Collapse
|
50
|
Tanaka S, Ueo H, Mafune K, Mori M, Wands JR, Sugimachi K. A novel isoform of human fibroblast growth factor 8 is induced by androgens and associated with progression of esophageal carcinoma. Dig Dis Sci 2001; 46:1016-21. [PMID: 11341643 DOI: 10.1023/a:1010753826788] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Human esophageal carcinomas occur more frequently in males, suggesting that androgens may play a role in the regulation of gene expression associated with malignant transformation. We previously established an androgen-sensitive squamous cell carcinoma line, KSE-1, from a male patient with esophageal cancer; recently a novel isoform of human fibroblast growth factor 8 (FGF8f, isoform FGF8b) was identified and expressed following androgen stimulation of KSE-1 cells. The predicted amino acid sequence of FGF8f contained an additional 29 amino acids when compared to FGF8b. Flutamide, an androgen antagonist, inhibited both FGF8b and FGF8f transcription in a dose-dependent manner. Tissue analysis from tumors revealed FGF8b expression in 24 of 41 male, but in 0 of 9 female esophageal carcinomas (58.5%), and none in adjacent normal esophageal mucosa. In addition, FGF8f was detected in 9 of 24 FGF8b-positive tumors (37.5%), and this observation was significantly associated with a poor prognosis (P < 0.001). Our observations suggest that androgenic exposure will induce FGF isoforms in tumor cells, and expression of these growth factors is associated with the prevalence and prognosis of esophageal carcinoma in males.
Collapse
Affiliation(s)
- S Tanaka
- Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan
| | | | | | | | | | | |
Collapse
|